TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07583446: A Randomized, Double-blind, Phase 2b/3 Clinical Study of Istaroxime Combined With Standard Care Versus Placebo and Standard of Care for the Treatment of Cardiogenic Shock (CS) Society for Cardiovascular Angiography and I

Sponsor: Seismic Pharmaceuticals Operations LLC · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 600 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,961,280

Rescue Site Savings

+$8,546,344

Unlock Full NCT07583446 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07583446 Rescue Dossier →